|
Certain drugs when taken by the oral route, are absorbed only from certain segments in the gastrointestinal tract . Since specific transport mechanisms are involved in their uptake, their absorption cannot be increased by just increasing the dose.
Our lead molecule, SUN-G 44, is a prodrug of the currently marketed drug gabapentin, which is used for the treatment of neuropathy andseizures. The molecular modifications in SUN-G 44’s structure allows for better absorption because of utilization of commonly available transport mechanisms.
In preliminary animal studies, on equivalent dosage, this molecule was found to be far better absorbed and safe, when compared to existing products as well as competing products currently in phase III studies internationally. This profile indicates the possibility of administering a higher dose, formulating this as a once-a-day product, and better safety. This molecule will now enter further stages of preclinical and clinical testing.
The chemical delivery system design used in SUN-G 44 can be extended to develop prodrugs of other molecules having similar limitation of poor oral absorption.
| 
Active Projects in Drug Discovery in focused therapy areas with known biology.
